Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Rev Med Suisse ; 20(884): 1456-1463, 2024 Aug 28.
Artigo em Francês | MEDLINE | ID: mdl-39219386

RESUMO

Gastroparesis is a pathology associating upper digestive symptoms, such as nausea and vomiting, with impaired gastric emptying in the absence of mechanical gastric or duodenal obstruction. It has a major impact on patients' quality of life, can lead to undernutrition, and -increases overall mortality. Several schools of thought converge on the hypothesis of a clinico--pathological spectrum of gastric neuro-muscular dysfunction encompassing gastroparesis and functional dyspepsia, in particular the subtype known as "postprandial distress syndrome". Its management includes non--pharmacological interventions, such as hygienic--dietary measures, pharmacological interventions using prokinetic, antiemetic or neuromodulatory treatments, and endoscopic interventions.


La gastroparésie est une pathologie associant des symptômes ­digestifs hauts, tels que des nausées et des vomissements, à un défaut de la vidange gastrique en l'absence d'une obstruction ­mécanique gastrique ou duodénale. Elle a un fort retentissement sur la qualité de vie des patients, peut amener à la dénutrition et augmente globalement la mortalité. Plusieurs courants de pensée convergent vers l'hypothèse d'un spectre clinicopathologique de dysfonction neuromusculaire gastrique englobant la gastroparésie et la dyspepsie fonctionnelle, notamment du sous-­type appelé « syndrome de détresse postprandiale ¼. Sa prise en charge ­comprend des interventions non pharmacologiques, telles que des mesures hygiénodiététiques, des interventions pharmacologiques à l'aide de traitements procinétiques, anti­émétiques ou encore neuromodulateurs, et des interventions ­endoscopiques.


Assuntos
Gastroparesia , Gastroparesia/terapia , Gastroparesia/diagnóstico , Gastroparesia/etiologia , Humanos , Qualidade de Vida , Esvaziamento Gástrico/fisiologia , Dispepsia/terapia , Dispepsia/diagnóstico , Dispepsia/etiologia
2.
J Gen Intern Med ; 2023 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-38093025

RESUMO

BACKGROUND: The simplified HOSPITAL score is an easy-to-use prediction model to identify patients at high risk of 30-day readmission before hospital discharge. An earlier stratification of this risk would allow more preparation time for transitional care interventions. OBJECTIVE: To assess whether the simplified HOSPITAL score would perform similarly by using hemoglobin and sodium level at the time of admission instead of discharge. DESIGN: Prospective national multicentric cohort study. PARTICIPANTS: In total, 934 consecutively discharged medical inpatients from internal general services. MAIN MEASURES: We measured the composite of the first unplanned readmission or death within 30 days after discharge of index admission and compared the performance of the simplified score with lab at discharge (simplified HOSPITAL score) and lab at admission (early HOSPITAL score) according to their discriminatory power (Area Under the Receiver Operating characteristic Curve (AUROC)) and the Net Reclassification Improvement (NRI). KEY RESULTS: During the study period, a total of 3239 patients were screened and 934 included. In total, 122 (13.2%) of them had a 30-day unplanned readmission or death. The simplified and the early versions of the HOSPITAL score both showed very good accuracy (Brier score 0.11, 95%CI 0.10-0.13). Their AUROC were 0.66 (95%CI 0.60-0.71), and 0.66 (95%CI 0.61-0.71), respectively, without a statistical difference (p value 0.79). Compared with the model at discharge, the model with lab at admission showed improvement in classification based on the continuous NRI (0.28; 95%CI 0.08 to 0.48; p value 0.004). CONCLUSION: The early HOSPITAL score performs, at least similarly, in identifying patients at high risk for 30-day unplanned readmission and allows a readmission risk stratification early during the hospital stay. Therefore, this new version offers a timely preparation of transition care interventions to the patients who may benefit the most.

3.
Rev Med Suisse ; 18(764-5): 31-34, 2022 Jan 19.
Artigo em Francês | MEDLINE | ID: mdl-35048576

RESUMO

Among the recent advances in gastroenterology, colonoscopy with artificial intelligence is associated with a better quality of screening. In refractory UC, Ozanimod seems to be an interesting salvage treatment, which still needs to be validated by Swissmedic. Among the direct-acting anticoagulants, Rivaroxaban is more frequently associated with GI bleeding. The classification of oesophageal motor disorders has been recently revised, the Chicago v4.0 classification should be applied in diagnostic management. The use of Semaglutide seems to show very promising results in the management of metabolic steatosis. SARS-CoV-2 infection can be complicated by biliary tract disease, which can progress to hepatocellular failure.


Parmi les récentes avancées en gastroentérologie, la coloscopie couplée à une intelligence artificielle est associée à un dépistage de meilleure qualité. Lors de rectocolite hémorragique réfractaire, l'ozanimod semble être un traitement de sauvetage intéressant, qui doit encore être validé par Swissmedic. Parmi les anticoagulants à action directe, le rivaroxaban est plus fréquemment associé aux hémorragies digestives. La classification des troubles moteurs de l'œsophage a fait l'objet d'une révision récente, la classification de Chicago v4.0 doit être appliquée dans la prise en charge diagnostique. L'utilisation du sémaglutide semble montrer des résultats très prometteurs dans la prise en charge de la stéatose métabolique. L'infection par le virus à SARS-CoV-2 peut se compliquer d'une atteinte des voies biliaires, pouvant évoluer jusqu'à l'insuffisance hépatocellulaire.


Assuntos
COVID-19 , Gastroenterologia , Inteligência Artificial , Colonoscopia , Humanos , SARS-CoV-2
4.
Rev Med Suisse ; 17(748): 1453-1456, 2021 Sep 01.
Artigo em Francês | MEDLINE | ID: mdl-34468096

RESUMO

Treatment of hepatitis C has known major progress thanks to direct-acting antivirals resulting in the healing, defined by a viral clearance (sustained virological response [SVR]), in the vast majority of patients. However, there is a residual risk of progressive liver damage in a minority of patients, potentially leading to complications such as liver decompensation, hepatocellular carcinoma and/or death. This article discusses the current knowledge of residual liver disease after treatment, the impact of comorbidities and the factors potentially predicting patients at risk of complications and warranting surveillance.


Le traitement de l'hépatite C a connu des progrès majeurs grâce aux antiviraux directs, permettant la guérison des patients, définie par une réponse virologique soutenue dans la grande majorité des cas. Il existe cependant un risque résiduel de progression de la maladie hépatique pour une faible proportion de patients pouvant entraîner un risque de complications majeures, de type décompensation cirrhotique, carcinome hépatocellulaire et/ou décès. Dans cet article, nous traitons des connaissances actuelles concernant le risque résiduel d'hépatopathie après traitement, de l'impact des comorbidités mais également des facteurs permettant d'identifier les patients à risque de complication et justifiant une surveillance.


Assuntos
Carcinoma Hepatocelular , Hepatite C Crônica , Hepatite C , Neoplasias Hepáticas , Antivirais/uso terapêutico , Carcinoma Hepatocelular/epidemiologia , Carcinoma Hepatocelular/etiologia , Hepacivirus , Hepatite C/complicações , Hepatite C/tratamento farmacológico , Hepatite C/epidemiologia , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/epidemiologia , Humanos , Cirrose Hepática/tratamento farmacológico , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/etiologia
5.
Rev Med Suisse ; 16(704): 1560-1563, 2020 Sep 02.
Artigo em Francês | MEDLINE | ID: mdl-32880112

RESUMO

Foreign bodies ingestion is a common event, with a potential morbidity and mortality. In the majority of cases, the foreign bodies pass through the digestive tract without any complication. An endoscopy for removal of the foreign body is necessary in 10 to 20 % of cases and a surgical intervention is required in < 1 % of cases. In this article, we describe the clinical presentation, the potential complications, as well as the timing and endoscopic technics of foreign bodies retrieval, essentially based on the European Society of Gastrointestinal Endoscopy recommendations.


L'ingestion de corps étrangers est un événement fréquent, potentiellement grevée d'une morbi-mortalité et engendrant des coûts importants. Dans la majorité des cas, les corps étrangers suivent le tube digestif sans complication. Une endoscopie est nécessaire dans 10 à 20 % des cas et une intervention chirurgicale pour extraction du corps étranger/complications dans moins de 1 % des cas. Dans cet article, nous traitons de la prise en charge des corps étrangers chez l'adulte et passons en revue leur présentation clinique, leurs complications potentielles, ainsi que les délais et modalités de la prise en charge endoscopique basée essentiellement sur les recommandations de la Société européenne d'endoscopie digestive.


Assuntos
Endoscopia Gastrointestinal/métodos , Endoscopia Gastrointestinal/normas , Corpos Estranhos/cirurgia , Trato Gastrointestinal/cirurgia , Humanos , Guias de Prática Clínica como Assunto
6.
Rev Med Suisse ; 15(660): 1478-1482, 2019 Aug 28.
Artigo em Francês | MEDLINE | ID: mdl-31496170

RESUMO

Digestive endoscopy has met an enormous progress over the last decade, both in terms of diagnosis and treatment of gastro-intestinal diseases. This review article presents the role of confocal endomicroscopy in the management of pancreatic cysts. Moreover, it resumes the most important novel therapeutic endoscopic techniques, some already available in expert centers such as G-POEM or biliary drainage by Axios stent system and spiral enteroscopy, as well as techniques undergoing validation such as the radiofrequency ablation of pancreatic tumors and the bariatric and metabolic endoscopy techniques.


L'endoscopie digestive a connu de grandes avancées au cours de la dernière décennie, à la fois sur les plans diagnostique et thérapeutique. Cet article fait le point sur le rôle de l'endomicroscopie confocale dans les kystes pancréatiques et sur plusieurs techniques d'endoscopie thérapeutique, certaines déjà disponibles dans les centres experts comme le G-POEM (pylorotomie endoscopique), le drainage biliaire par prothèse d'apposition et l'entéroscopie spiralée motorisée, ou encore en cours de développement, comme l'ablation par radiofréquence des tumeurs pancréatiques ou l'endoscopie bariatrique et métabolique.


Assuntos
Endoscopia Gastrointestinal/tendências , Gastroenteropatias , Drenagem , Gastroenteropatias/diagnóstico , Humanos , Laparoscopia , Neoplasias Pancreáticas/cirurgia , Stents
7.
Cell Rep ; 19(3): 451-460, 2017 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-28423309

RESUMO

Flavivirus infections by Zika and dengue virus impose a significant global healthcare threat with no US Food and Drug Administration (FDA)-approved vaccination or specific antiviral treatment available. Here, we present the discovery of an anti-flaviviral natural product named cavinafungin. Cavinafungin is a potent and selectively active compound against Zika and all four dengue virus serotypes. Unbiased, genome-wide genomic profiling in human cells using a novel CRISPR/Cas9 protocol identified the endoplasmic-reticulum-localized signal peptidase as the efficacy target of cavinafungin. Orthogonal profiling in S. cerevisiae followed by the selection of resistant mutants pinpointed the catalytic subunit of the signal peptidase SEC11 as the evolutionary conserved target. Biochemical analysis confirmed a rapid block of signal sequence cleavage of both host and viral proteins by cavinafungin. This study provides an effective compound against the eukaryotic signal peptidase and independent confirmation of the recently identified critical role of the signal peptidase in the replicative cycle of flaviviruses.


Assuntos
Produtos Biológicos/farmacologia , Vírus da Dengue/fisiologia , Lipopeptídeos/farmacologia , Replicação Viral/efeitos dos fármacos , Zika virus/fisiologia , Produtos Biológicos/química , Sistemas CRISPR-Cas/genética , Vírus da Dengue/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Genoma Humano , Genômica , Células HCT116 , Humanos , Lipopeptídeos/química , Proteínas de Membrana , Subunidades Proteicas/metabolismo , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/genética , Serina Endopeptidases , Proteínas Virais/metabolismo , Zika virus/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA